0001104659-20-140992.txt : 20201231
0001104659-20-140992.hdr.sgml : 20201231
20201231163027
ACCESSION NUMBER: 0001104659-20-140992
CONFORMED SUBMISSION TYPE: 5
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201231
FILED AS OF DATE: 20201231
DATE AS OF CHANGE: 20201231
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WEISS MICHAEL S
CENTRAL INDEX KEY: 0001038977
FILING VALUES:
FORM TYPE: 5
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32639
FILM NUMBER: 201429132
MAIL ADDRESS:
STREET 1: 750 LEXINGTON AVE
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TG THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001001316
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 363898269
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
BUSINESS PHONE: (212) 554-4484
MAIL ADDRESS:
STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
FORMER COMPANY:
FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030310
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC
DATE OF NAME CHANGE: 20000330
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19960703
5
1
tm2039708-1_form5.xml
OWNERSHIP DOCUMENT
X0306
5
2020-12-31
0
0
0
0001001316
TG THERAPEUTICS, INC.
TGTX
0001038977
WEISS MICHAEL S
2 GANSEVOORT STREET, 9TH FLOOR
NEW YORK
NY
10014
1
1
0
0
CEO and President
COMMON STOCK
2020-09-10
5
G
0
525000
0
D
13909214
D
COMMON STOCK
2020-09-25
5
G
0
2500
0
D
13906714
D
COMMON STOCK
2020-12-15
5
G
0
834877
0
D
13071837
D
COMMON STOCK
2020-12-15
5
G
0
1700
0
D
13070137
D
COMMON STOCK
2020-12-15
5
G
0
200
0
D
13069937
D
COMMON STOCK
2020-12-22
5
G
0
200
0
D
13069737
D
COMMON STOCK
2020-12-28
5
G
0
1000
0
D
13068737
D
COMMON STOCK
2020-12-28
5
G
0
655
0
D
13068082
I
See Note 3
Reflects the transfer of shares of TG Therapeutics stock to the Weiss Family and Descendants Trust.
Reflect the transfer of shares as a bona fide gift to various 501(c)(3) charitable organizations.
Included in Mr. Weiss' beneficial ownership are 4,909,355 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest.
/s/ Michael Weiss
2020-12-31